{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-17984236-lanreotide:v1","objectPathId":"pubmed-pmid-17984236-lanreotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-17984236-lanreotide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-17984236-lanreotide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-17984236-lanreotide-v1.md"},"story":{"slug":"pubmed-pmid-17984236-lanreotide","version":1,"domain":"Literature metadata","dateInSource":"2016-11-24","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["lanreotide"],"peptides":[{"slug":"lanreotide","url":"https://peptidescanner.com/peptides/lanreotide/"}]},"claims":[{"id":"headline","text":"Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.","sourceIds":["pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1"]},{"id":"summary","text":"PubMed lists PMID 17984236 in European journal of endocrinology as Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 2007-11 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1"]},{"id":"paragraph-1","text":"PubMed lists PMID 17984236 in European journal of endocrinology as Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 2007-11 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1"]}],"sources":[{"id":"pubmed-observation-pmid-17984236-2016-11-24-635b9cdf9cc1","name":"PubMed","sourceClass":"A","title":"Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. · retained source version 1:2016-11-24:current:635b9cdf9cc133e7bc7ea8702d983def1a91d3e44fcde7fdfc4ee6025676ba6f","url":"https://pubmed.ncbi.nlm.nih.gov/17984236/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"1b0a8a0127cbb734eb0984c5dafedfd59d5cb38e95ae7b41377701e6f4a98bd1","tierARecordSha256":"fbfdcaeacfb14038e7d6fbf52cb15689920cb6a44aa04c432b7ce22a66da2c30"},"integrity":{"algorithm":"sha256","contentSha256":"3a48c263b5ec4d5dba7f9f7c4932317cfc6080d1c9e9e435c3bf344937394e8f"}}